@stephenvliu : Impact of TP53 mutations in squamous NSCLC? Retrospective analysis @ClinicalLung of 2250 pts showed TP53mt subset had better mOS with immunotherapy (24.7m vs 12.0m) and longer mPFS (9.6m vs 3.2m) vs TP53wt. No differences in chemotherapy outcomes. clinical-lung-cancer.com/article/S1525-… • TwiCopy

Stephen V Liu, MD

@stephenvliu

+ Follow

Director of Thoracic Oncology & Developmental Therapeutics @Georgetown @LombardiCancer; Host @IASLC Podcast; Chair #DCLung24 #TexasLung25 #HereWeGo #LetsGoBucs

ID: 377425889

linkhttps://www.medstarhealth.org/doctors/stephen-liu-md calendar_today21-09-2011 15:17:53

18,18K Tweet

25,25K Followers

3,3K Following

Stephen V Liu, MD

@stephenvliu

9 months ago

Impact of TP53 mutations in squamous NSCLC? Retrospective analysis Clinical Lung Cancer of 220 pts showed TP53mt subset had better mOS with immunotherapy (24.7m vs 12.0m) and longer mPFS (9.6m vs 3.2m) vs TP53wt. No differences in chemotherapy outcomes. clinical-lung-cancer.com/article/S1525-…